-
Economic liberalisation policies of the Government of India.
-
India's membership of the WTO and product patent regime from 2005
-
Removal of quantitative restrictions on industry.
-
Globalisation of trading: no restrictive list for imports and tariffs.
-
Maintain the strength In Process Development R & D.
-
Development of environmentally benign processes.
-
Expand the ambit of production of biotechnology products.
-
Steadily expand the ambit of rural marketing to cover the entire population by 2010.
-
Create world class / world scale manufacturing facilities following international industry regulatory standards for c-GMP.
-
Increase investment substantially in New Drug Delivery Research through NRls and venture capital.
-
Net-work or outsource drug development.
-
Become a leading Cluster for clinical research, following GCP & GLP guidelines.
-
Create a special focus in developing herbal drugs.
-
Become a big supplier of combinatorial chemistry libraries.
-
SMEs can become "Specialty clusters to become niche player in
-
Custom synthesis and specialised generic drugs.
-
Better use of existing drugs.
-
New improved chemical entities
(NCES).
-
Herbal drugs.
-
Biotechnology generic production. CRO for clinical research.
-
Bioinformatics Centres.
-
Rural I social marketing.
-
Contract process development research.
-
Transition metal catalysts.
-
Green Chemistry, synthesis under environmentally benign conditions.
